Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06389877
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-04-22
Brief Title:
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency AATD
Sponsor:
Beam Therapeutics Inc
Organization:
Beam Therapeutics Inc
Study Overview
Official Title:
A Phase 12 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency AATD-Associated Lung Disease andor Liver Disease
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 12 multicenter open-label dose-exploration Phase 1 and dose-expansion Phase 2 study to evaluate the safety tolerability PKPD and efficacy of BEAM-302 in adult patients with AATD-associated lung disease andor liver disease and to determine the optimal biological dose OBD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None